Matriptase Activation for Abnormal Cell Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective means to determine the presence or absence of abnormal lymphoid cells or abnormal myeloid cells in cell samples and monitor their progression, as existing technologies do not adequately utilize the activation and measurement of matriptase levels for diagnostic purposes.
Innovation Solution
Subjecting cell samples to conditions that activate inactive matriptase, followed by measuring activated matriptase levels using acidic buffers and fluorogenic substrates to detect abnormal cell types, with comparisons to control levels for diagnostic and monitoring purposes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used to detect abnormal lymphoid or myeloid cells, then the diagnostic process is simple, but the detection accuracy and reliability are insufficient
Solution Approach 1:
The method applies preliminary activation treatment to convert inactive matriptase into active form before measurement. This preliminary action ensures that the measured matriptase levels accurately reflect the true state of abnormal cells, improving detection accuracy without requiring complex real-time activation mechanisms during measurement.
Solution Approach 2:
The invention introduces an activation step as an intermediary process between sample collection and measurement. This intermediary activation treatment enables the detection method to reliably distinguish abnormal cells from normal cells by converting dormant matriptase markers into detectable active forms, thereby improving measurement precision while maintaining procedural simplicity.
2Reliability
If matriptase activation and measurement steps are added to detect abnormal cells, then detection accuracy improves, but the procedure complexity increases
Solution Approach 1:
The activation step is performed as a preliminary treatment before measurement, ensuring reliable detection of abnormal cells through matriptase activation. This approach maintains diagnostic reliability by converting inactive matriptase to active form while keeping the procedure straightforward through sequential simple steps rather than complex simultaneous processes.
Solution Approach 2:
The method changes the activation state parameter of matriptase from inactive to active through controlled treatment conditions. This parameter change enables reliable differentiation between abnormal and normal cells while maintaining procedural simplicity by using standard biochemical activation conditions rather than complex measurement systems.
3Productivity
If existing protease measurement methods are used, then the measurement process is straightforward, but the ability to detect abnormal cell presence is insufficient
Solution Approach 1:
The method applies preliminary activation treatment to matriptase before measurement to ensure that abnormal cells are properly detected. This preliminary action transforms dormant matriptase markers in abnormal cells into active detectable forms, significantly improving detection accuracy while maintaining efficient throughput through a single-step activation protocol.
Solution Approach 2:
The invention changes the activation state parameter of matriptase to enable effective detection of abnormal cells. By controlling the activation parameter through standardized treatment conditions, the method achieves both high detection efficiency and improved measurement precision for identifying abnormal lymphoid or myeloid cells.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method allows for the accurate detection of abnormal lymphoid or myeloid cells and monitoring of treatment efficacy by measuring changes in activated matriptase levels over time, providing a reliable indicator of cell abnormality or treatment effectiveness.
Implementation Method 1
subjecting the cell sample to conditions that will activate any inactive matriptase present in the cell sample
Implementation Method 2
measuring the levels of activated matriptase in the cell sample
Data Source
AI summary
The present invention relates to methods of determining the presence or absence of abnormal lymphoid cells or abnormal myeloid cells in a cell sample, with the methods comprising subjecting the cell sample to conditions that will activate any inactive matriptase present in the cell sample and measuring the levels of activated matriptase in the cell sample. Once measured, these levels can then be compared to control levels of active matriptase to determine if the cell sample has elevated levels of activated matriptase over control levels of active matriptase. An elevation in the levels of activated matriptase in the cell sample is indicative that the cell sample contains abnormal lymphoid cells or abnormal myeloid cells.